| Existing agents, novel agents, or transplantation for high-risk MDS |
|
Hematology. American Society of Hematology. Education Program |
Myelodysplastic Syndromes (MDS) |
| Lowering the boom on lower-risk myelodysplastic syndromes |
|
Hematology. American Society of Hematology. Education Program |
Myelodysplastic Syndromes (MDS) |
| Monitoring and treatment of MDS in genetically susceptible persons |
|
Hematology. American Society of Hematology. Education Program |
Myelodysplastic Syndromes (MDS) |
| Genetic predisposition to MDS: diagnosis and management |
|
Hematology. American Society of Hematology. Education Program |
Myelodysplastic Syndromes (MDS) |
| Idiopathic aplastic anemia vs hypocellular myelodysplastic syndrome |
|
Hematology. American Society of Hematology. Education Program |
Aplastic Anemia |
| Expert consensus on the management of pharmacodynamic breakthrough-hemolysis in treated paroxysmal nocturnal hemoglobinuria |
|
Hematology. |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Switching patients with PNH from pegcetacoplan to iptacopan: a case series |
|
Hematology. |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Real-world clinical outcomes and treatment response in complement inhibitor experienced and naïve PNH patients prescribed pegcetacoplan in Europe and Canada |
|
Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Myelodysplastic syndromes with ring sideroblasts |
|
Hematological Oncology |
Myelodysplastic Syndromes (MDS) |
| Kinetics of Pre-Myelodysplastic Syndromes Blood Values Correlate with Disease Risk and Survival |
|
Hematological Oncology |
Myelodysplastic Syndromes (MDS) |
